Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab versus placebo with glucocorticoid taper in relapsing polymyalgia rheumatica
NL-OMON59650Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of secukinumab in polymyalgia rheumatica (PMR) (3 arms), sponsored by Novartis. Primary endpoint: Proportion of participants achieving sustained remission at Week 52. Started Mar 2024; status: completed.
02
Drugs
secukinumab
03
Conditions
polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on NL-OMON59650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59650.